Literature DB >> 6608586

Treatment of Sézary syndrome with cyclosporin A.

L Puttick, A Pollock, E Fairburn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6608586      PMCID： PMC1439517          DOI： 10.1177/014107688307601216

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  11 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Erythroderma with atypical lymphocytes. (Sézary syndrome).

Authors:  R K Winkelmann; J W Linman
Journal:  Am J Med       Date:  1973-08       Impact factor: 4.965

3.  Antiproliferative activity of cyclosporin A on human T-lymphoblastic leukaemia cell line.

Authors:  P Foa; A T Maiolo; L Baldini; A Maisto; M Spano; G Starace; F Quarto di Palo; E E Polli
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

Review 4.  Cyclosporin A.

Authors:  P J Morris
Journal:  Transplantation       Date:  1981-11       Impact factor: 4.939

5.  Cyclosporin A blocks receptors for HLA-DR antigens on T cells.

Authors:  R Palacios; G Möller
Journal:  Nature       Date:  1981-04-30       Impact factor: 49.962

6.  Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings.

Authors:  E H Epstein; D L Levin; J D Croft; M A Lutzner
Journal:  Medicine (Baltimore)       Date:  1972-01       Impact factor: 1.889

7.  Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

8.  Cyclosporin-A is selectively cytotoxic to human leukemic T cells in vitro.

Authors:  T H Tötterman; A Danersund; K Nilsson; A Killander
Journal:  Blood       Date:  1982-05       Impact factor: 22.113

9.  Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal.

Authors:  A W Thomson; P H Whiting; J T Blair; R J Davidson; J G Simpson
Journal:  Transplantation       Date:  1981-10       Impact factor: 4.939

10.  Cyclosporin A for the treatment of graft-versus-host disease in man.

Authors:  R L Powles; A J Barrett; H Clink; H E Kay; J Sloane; T J McElwain
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321
View more
  3 in total

1.  Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour.

Authors:  W Van de Vrie; R L Marquet; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Growth inhibition of human gastrointestinal cancer cells by cyclosporin A.

Authors:  M Piontek; R Porschen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro.

Authors:  P R Twentyman; K A Wright; H M Wallace
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.